Risk-share pays off for Lilly as it takes back migraine antibody

Eli Lilly is acquiring all rights to a therapeutic migraine antibody that it discovered and then licensed to new company Arteaus Therapeutics for development in 2011.

Eli Lilly is acquiring all rights to a therapeutic migraine antibody that it discovered and then licensed to new company Arteaus Therapeutics for development in 2011.

Arteaus was formed with an $18m investment from Atlas Venture and OrbiMed solely for the development of the calcitonin gene-related...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category